Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01733355
Other study ID # T807000
Secondary ID
Status Terminated
Phase Phase 0
First received September 25, 2012
Last updated July 18, 2013
Start date July 2012
Est. completion date March 2013

Study information

Verified date July 2013
Source Avid Radiopharmaceuticals
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

[F-18]T807 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.


Description:

Siemens Molecular Imaging (SMI) is seeking to determine if [F-18]T807 might be useful as a non-invasive assessment tool in the clinical evaluation of subjects with conditions associated with tau protein aggregates, such as Alzheimer's disease. The information collected under this exploratory study will not be used for diagnostic purposes, assessments of the participant's response to therapy or for clinical management of the participants. However, this exploratory study will provide baseline information on the safety, biodistribution, and dosimetry of [F-18]T807. These data will aid in the design of future studies of [F-18]T807 in patients with Alzheimer's disease. Overall, this study will provide initial data that inform the development of [F-18]T807 as the first PET imaging agent for human tau protein related pathology.


Recruitment information / eligibility

Status Terminated
Enrollment 11
Est. completion date March 2013
Est. primary completion date March 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 55 Years and older
Eligibility Inclusion Criteria; Low Probability for AD Participants (Group 1)

- Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity)

- Participant provides written informed consent

- Participant is capable of complying with study procedures

- Participant is capable of communicating with study personnel

- Participant understands and speaks English

- Participant has at least an 8th Grade education

- In the Investigator's opinion, participant has a low probability of being currently positive for AD as determined by a Mini Mental State Examination (MMSE = 28) defined in APPENDIX VI of protocol T807000, IND 114102

- Participant has no significant hepatic or renal disease as defined by previous medical history and lab results are within the following ranges:

- Total bilirubin within 2x institutional upper limits of normal

- AST (SGOT) = 2.5 x institutional upper limits of normal

- ALT (SGPT) = 2.5 x institutional upper limits of normal

- Creatinine = 2x institutional upper limits of normal

- BUN within 2x institutional upper limits of normal

High Probability for AD Participants (Group 2)

- Participant has reached his or her 55th birthday at the time of informed consent (Participant is male or female of any race / ethnicity)

- Participant or participant's legally acceptable representative provides written informed consent

- Participant is capable of complying with study procedures

- Participant is capable of communicating with study personnel

- Participant understands and speaks English

- Participant has at least an 8th Grade education

- In the Investigator's opinion, participant has a high probability of being currently positive for AD that is determined by a Mini Mental State Examination (MMSE < 17) defined in APPENDIX VI of protocol T807000, IND 114102.

- Participant has no significant hepatic or renal disease as defined by previous medical history, and lab results are within the following ranges:

- Total bilirubin within 2x institutional upper limits of normal

- AST (SGOT) = 2.5 x institutional upper limits of normal

- ALT (SGPT) = 2.5 x institutional upper limits of normal

- Creatinine = 2x institutional upper limits of normal

- BUN within 2x institutional upper limits of normal

Exclusion Criteria; All Participants

- Female participant is pregnant or nursing

- Participant has prior history of stroke or other condition of the head or neck that, in the Investigator's opinion, might affect circulation to the head or image interpretation

- Participant has other neurodegenerative disease that is associated with cognitive impairment or dementia

- Participant has a medical condition that might be associated with elevated amyloid levels, such as amyloid angiopathy, familial amyloidosis, chronic kidney dialysis, Down's syndrome

- Participant has a history of significant cerebrovascular disease

- Participant has previously received [F-18]T807 at any time

- Participant has been involved in an investigative, radioactive research procedure within the past 14 days

- Participant has any other condition or personal circumstance that, in the judgment of the Investigator, might interfere with the collection of complete data or data quality

- Participant has a history in the last five years of significant prescription or non-prescription drug or alcohol abuse, including but not limited to marijuana, cocaine, heroin or derivatives

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label


Related Conditions & MeSH terms


Intervention

Radiation:
[F18] T807
Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi

Locations

Country Name City State
United States Research Site Irvine California
United States Research Site Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Avid Radiopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the bio-distribution and radiation dosimetry of [F-18]T807 in participants with low probability of Alzheimer's disease (AD) using PET/CT whole body imaging up to 15 days per patient No
Primary To evaluate the metabolism of [F-18]T807 in participants with low probability of AD using serial blood samples collected pre- and post-IP administration up to 15 days per patient No
Primary To evaluate [F-18]T807 uptake and signal/background information in brain PET/CT imaging of participants with a high probability of currently being positive for AD and age-matched participants with a low probability of currently being positive for AD upto 15 days per patient No
Primary To assess the safety of IV administration of [F-18]T807 Safety will be monitored for all subjects by the:
Number of subjects experiencing adverse events from baseline to 24 hours post-administration.
Number and type of adverse events.
Changes in clinical laboratory assessments (CBC and clinical chemistry)from baseline to 24 hours post administration.
Changes in physical examination from baseline to 24 hours post administration.
Changes in vital sign measurements (systolic blood pressure [mmHg]; diastolic blood pressure [mmHg], pulse rate [bpm] and body temperature) from baseline prior to [F-18]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration)and at 24 hours post administration.
Changes in ECG measurements, from baseline prior to [F-18]T807 administration, at 60 +/- 15 minutes post administration, at the end of the final imaging session (approximately 100 minutes post administration) and at 24 hours post administration.
up to 24 hours post [F18]T807 administration Yes
Secondary To begin collection of baseline [F-18]T807 PET/CT imaging data The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of [F-18]T807 up to 15 days per patient No
Secondary To gain information to improve the study design for the conduct of future trials The secondary endpoint of this investigational study is the collection of baseline whole body PET/CT images and PET/CT images of the brain, following administration of [F-18]T807 up to 15 days per patient No
See also
  Status Clinical Trial Phase
Completed NCT02409082 - Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures N/A
Terminated NCT02565511 - A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Phase 2/Phase 3
Completed NCT01993836 - Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care Phase 4
Terminated NCT05097131 - An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
Completed NCT00448799 - Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls Phase 1
Recruiting NCT04639050 - Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease Phase 1/Phase 2
Terminated NCT06424236 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Phase 2/Phase 3
Active, not recruiting NCT05891496 - A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease Phase 3
Terminated NCT01723488 - A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808 Phase 0
Completed NCT00911690 - Establishment of a Bank of Biospecimens for Future Research on Age-related Cognitive Disorders N/A
Recruiting NCT01479855 - Multiple Nutritional Deficiencies Causing Dementia of the Alzheimer Type N/A
Completed NCT01469351 - Identifying Potential Effects of Liraglutide on Degenerative Changes N/A
Completed NCT00439010 - Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects Phase 1
Recruiting NCT05269394 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) Phase 2/Phase 3
Recruiting NCT01760005 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 Phase 2/Phase 3
Completed NCT04623242 - Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Phase 2/Phase 3
Suspended NCT05552157 - A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation Phase 2/Phase 3
Completed NCT04023994 - A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants Phase 1
Terminated NCT03131453 - A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease Phase 2/Phase 3
Completed NCT01946243 - The Feasibility of Florbetapir Quantitation Phase 4